PIK3CA-related Overgrowth Spectrum
5 clinical trials · Condition
◉ Watch PIK3CA-related Overgrowth Spectrum
| Record | Firm | Date |
|---|---|---|
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (NCT05983159) | Murdoch Childrens Research Institute | 2024-09-13 |
| A Study of the Epidemiology and Hospital Management of Patients With PROS in France (NCT07222423) | Novartis Pharmaceuticals | 2024-01-15 |
| National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) (NCT05563831) | Institut National de la Santé Et de la Recherche Médicale, France | 2023-02-21 |
| Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study (NCT05294289) | Novartis Pharmaceuticals | 2022-05-16 |
| Study of Proteus Syndrome and Related Congenital Disorders (NCT00001403) | National Human Genome Research Institute (NHGRI) | 1994-04-27 |
Track PIK3CA-related Overgrowth Spectrum automatically
Every clearance here is in the API, with alerts when new ones post.